| (Values in U.S. Thousands) | Jun, 2017 | Jun, 2016 | Jun, 2015 | Jun, 2014 | Jun, 2013 |
| Sales | 190 | 560 | 70 | 80 | 1,140 |
| Sales Growth | -66.07% | +699.99% | -12.50% | -92.98% | -26.92% |
| Net Income | -8,040 | -16,550 | -5,500 | -6,950 | -800 |
| Net Income Growth | +51.42% | -200.91% | +20.86% | -768.75% | +42.45% |
Novogen Ltd Ads (NVGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
NOVOGEN LTD-ADR business is in the area of medicine know as degenerative diseases and disorders. Novogen is addressing this urgent area of medical need through the Novogen isoflavonoid technology platform - a platform that the Company believes offers the real prospect of not only treating, but also preventing, the onset of these common degenerative conditions. There are three divisions at Novagen: the pharmaceutical division, Marshall Edwards inc., and the consumer health division.